Boston Scientific Owes $42 Million as Stents Infringe Patent (1)

Boston Scientific Corp.'s Synergy brand of coronary stents infringes a patent the University of Texas owns and exclusively licensed to TissueGen Inc., a federal jury in Delaware said.

The Board of Regents of the University of Texas System and TissueGen convinced jurors that they deserve $42 million as a royalty for infringement that occurred between Nov. 20, 2017, and the patent’s Aug. 18, 2020, expiration, according to a verdict reached Tuesday and docketed Wednesday in the US District Court for the District of Delaware.

Jurors found the infringement was intentional, which gives the court the option to increase the award ...